1st Division of Internal Medicine and Hepato-Gastroenterology Unit, University Hospital of Ioannina, Ioannina 45500, Greece.
Hepatobiliary Pancreat Dis Int. 2012 Aug 15;11(4):434-7. doi: 10.1016/s1499-3872(12)60204-5.
Terlipressin has been shown to improve both pulmonary and systemic hemodynamics in stable cirrhotic patients with pulmonary hypertension, whereas other vasoconstrictors may cause pulmonary pressures to deteriorate. We investigated the pulmonary and systemic hemodynamic effects of the first terlipressin dose (2 mg) in 7 cirrhotic patients with PH presenting with variceal bleeding (n=4) or hepatorenal syndrome (n=3). Terlipressin decreased pulmonary vascular resistance (158.8+/-8.9 vs 186.5+/-13.9 dynes · sec · cm-5; P=0.003) together with an increase in systemic vascular resistance (2143+/-126 vs 1643+/-126 dynes · sec · cm-5; P<0.001). Terlipressin should be the vasoconstrictor treatment of choice when patients present with variceal bleeding or HRS.
特利加压素已被证明可改善稳定的伴有肺动脉高压的肝硬化患者的肺和全身血液动力学，而其他血管收缩剂可能会导致肺压恶化。我们研究了首剂特利加压素（2 毫克）在 7 例伴有静脉曲张出血（n=4）或肝肾综合征（n=3）的 PH 肝硬化患者中的肺和全身血液动力学效应。特利加压素降低肺血管阻力（158.8+/-8.9 对 186.5+/-13.9 达因·秒·厘米-5；P=0.003），同时增加全身血管阻力（2143+/-126 对 1643+/-126 达因·秒·厘米-5；P<0.001）。当患者出现静脉曲张出血或 HRS 时，特利加压素应作为首选的血管收缩剂治疗。
